DK0517221T3 - ((Arylalkylpiperidin-4-yl)-methyl)-2alfa,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-oner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler - Google Patents

((Arylalkylpiperidin-4-yl)-methyl)-2alfa,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-oner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler

Info

Publication number: DK0517221T3
Authority: DK; Denmark
Prior art keywords: arylalkylpiperidin; acenaphthylen; 2alpha; tetrahydro; drugs
Prior art date: 1991-06-07

Application number

DK92109467.8T

Other languages

Danish (da)

English (en)

Inventor

Bettina Spahl

Raymond W Kosley Jr

Original Assignee

Hoechst Roussel Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-07

Filing date

1992-06-04

Publication date

1996-04-22

1992-06-04 Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma

1996-04-22 Application granted granted Critical

1996-04-22 Publication of DK0517221T3 publication Critical patent/DK0517221T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Lubricants (AREA)
Pyridine Compounds (AREA)

DK92109467.8T 1991-06-07 1992-06-04 ((Arylalkylpiperidin-4-yl)-methyl)-2alfa,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-oner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler DK0517221T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/713,249 US5106856A (en)	1991-06-07	1991-06-07	[(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds

Publications (1)

Publication Number	Publication Date
DK0517221T3 true DK0517221T3 (da)	1996-04-22

Family

ID=24865395

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92109467.8T DK0517221T3 (da)	1991-06-07	1992-06-04	((Arylalkylpiperidin-4-yl)-methyl)-2alfa,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-oner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler

Country Status (23)

Country	Link
US (1)	US5106856A (hu)
EP (1)	EP0517221B1 (hu)
JP (1)	JP2961013B2 (hu)
KR (1)	KR100234445B1 (hu)
AT (1)	ATE131814T1 (hu)
AU (1)	AU646784B2 (hu)
CA (1)	CA2070714A1 (hu)
CZ (1)	CZ284591B6 (hu)
DE (1)	DE69206889T2 (hu)
DK (1)	DK0517221T3 (hu)
ES (1)	ES2081517T3 (hu)
FI (1)	FI101297B (hu)
GR (1)	GR3018558T3 (hu)
HU (1)	HU217967B (hu)
IE (1)	IE72199B1 (hu)
IL (1)	IL102118A (hu)
MX (1)	MX9202736A (hu)
NO (1)	NO178889C (hu)
NZ (1)	NZ243013A (hu)
PL (1)	PL169423B1 (hu)
RU (1)	RU2043989C1 (hu)
TW (1)	TW206214B (hu)
ZA (1)	ZA924109B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW248556B (hu) *	1993-01-18	1995-06-01	Takeda Pharm Industry Co
US6939879B2 (en) *	1998-08-28	2005-09-06	Aventis Pharmaceuticals Inc.	Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
HUP0104493A3 (en)	1998-09-30	2002-12-28	Takeda Pharmaceutical	Drugs for improving vesical excretory strength
CN109662964A (zh) *	2010-02-09	2019-04-23	约翰斯.霍普金斯大学	用于改善认知功能的方法和组合物
EP3034079B1 (en)	2010-11-15	2018-01-10	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
CA2891122C (en)	2012-11-14	2021-07-20	The Johns Hopkins University	Methods and compositions for treating schizophrenia
AU2014228512A1 (en)	2013-03-15	2015-10-01	Agenebio, Inc.	Methods and compositions for improving cognitive function
WO2014144663A1 (en)	2013-03-15	2014-09-18	The Johns Hopkins University	Methods and compositions for improving cognitive function
CA2934553C (en)	2013-12-20	2023-10-31	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112843005B (zh)	2015-05-22	2023-02-21	艾吉因生物股份有限公司	左乙拉西坦的延时释放药物组合物
MX2017015752A (es)	2015-06-19	2018-04-13	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
BR112019012821A2 (pt)	2016-12-19	2019-11-26	Agenebio Inc	derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2020013927A (es)	2018-06-19	2021-03-02	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
US20240132513A1 (en)	2022-08-19	2024-04-25	Agenebio, Inc.	Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2589934A (en) *	1950-08-24	1952-03-18	Abbott Lab	2-aminomethyl-tetrahydroacenapthones-1 and their preparation
US3391178A (en) *	1964-12-30	1968-07-02	Ernest E. Campaigne	Dialkylaminoalkyl 1-oxo-2alpha, 3, 4, 5-tetrahydroacenaphthen-2alpha-carboxylates
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2969359B2 (ja) *	1989-01-13	1999-11-02	武田薬品工業株式会社	環状アミン化合物

1991
- 1991-06-07 US US07/713,249 patent/US5106856A/en not_active Expired - Fee Related
1992
- 1992-05-23 TW TW081104034A patent/TW206214B/zh active
- 1992-06-04 FI FI922592A patent/FI101297B/fi not_active IP Right Cessation
- 1992-06-04 DK DK92109467.8T patent/DK0517221T3/da active
- 1992-06-04 EP EP92109467A patent/EP0517221B1/en not_active Expired - Lifetime
- 1992-06-04 ES ES92109467T patent/ES2081517T3/es not_active Expired - Lifetime
- 1992-06-04 AT AT92109467T patent/ATE131814T1/de not_active IP Right Cessation
- 1992-06-04 NZ NZ243013A patent/NZ243013A/en unknown
- 1992-06-04 DE DE69206889T patent/DE69206889T2/de not_active Expired - Fee Related
- 1992-06-05 NO NO922223A patent/NO178889C/no not_active IP Right Cessation
- 1992-06-05 JP JP4144694A patent/JP2961013B2/ja not_active Expired - Fee Related
- 1992-06-05 ZA ZA924109A patent/ZA924109B/xx unknown
- 1992-06-05 AU AU18015/92A patent/AU646784B2/en not_active Ceased
- 1992-06-05 IL IL10211892A patent/IL102118A/en not_active IP Right Cessation
- 1992-06-05 PL PL92294803A patent/PL169423B1/pl unknown
- 1992-06-05 KR KR1019920009765A patent/KR100234445B1/ko not_active IP Right Cessation
- 1992-06-05 HU HU9201887A patent/HU217967B/hu not_active IP Right Cessation
- 1992-06-05 CZ CS921713A patent/CZ284591B6/cs not_active IP Right Cessation
- 1992-06-06 RU SU925052251A patent/RU2043989C1/ru active
- 1992-06-08 MX MX9202736A patent/MX9202736A/es not_active IP Right Cessation
- 1992-06-08 CA CA002070714A patent/CA2070714A1/en not_active Abandoned
- 1992-07-01 IE IE921840A patent/IE72199B1/en not_active IP Right Cessation
1995
- 1995-12-28 GR GR950403690T patent/GR3018558T3/el unknown

Also Published As

Publication number	Publication date
IL102118A0 (en)	1993-01-14
PL294803A1 (en)	1993-07-26
AU646784B2 (en)	1994-03-03
DE69206889D1 (de)	1996-02-01
CA2070714A1 (en)	1992-12-08
HU217967B (hu)	2000-05-28
NO922223L (no)	1992-12-08
ZA924109B (en)	1993-02-24
EP0517221A1 (en)	1992-12-09
KR930000483A (ko)	1993-01-15
HU9201887D0 (en)	1992-08-28
FI101297B1 (fi)	1998-05-29
GR3018558T3 (en)	1996-03-31
KR100234445B1 (ko)	1999-12-15
JPH06116237A (ja)	1994-04-26
NO178889C (no)	1996-06-26
TW206214B (hu)	1993-05-21
FI922592A0 (fi)	1992-06-04
JP2961013B2 (ja)	1999-10-12
FI922592A (fi)	1992-12-08
ATE131814T1 (de)	1996-01-15
NZ243013A (en)	1995-04-27
IE921840A1 (en)	1992-12-16
IE72199B1 (en)	1997-04-09
HUT65605A (en)	1994-07-28
IL102118A (en)	1996-05-14
FI101297B (fi)	1998-05-29
CS171392A3 (en)	1992-12-16
NO178889B (no)	1996-03-18
DE69206889T2 (de)	1996-05-30
US5106856A (en)	1992-04-21
MX9202736A (es)	1993-01-01
AU1801592A (en)	1992-12-10
PL169423B1 (pl)	1996-07-31
EP0517221B1 (en)	1995-12-20
CZ284591B6 (cs)	1999-01-13
NO922223D0 (no)	1992-06-05
ES2081517T3 (es)	1996-03-16
RU2043989C1 (ru)	1995-09-20

Publication	Publication Date	Title
DK0517221T3 (da)	1996-04-22	((Arylalkylpiperidin-4-yl)-methyl)-2alfa,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-oner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
NO304980B1 (no)	1999-03-15	Substituerte 3-(aminoalkylamino)-1,2-benzisoksazoler og beslektede forbindelser, farmas°ytiske preparater inneholdende dem og deres anvendelse for fremstilling av legemidler
DK0509400T3 (da)	1996-10-28	1-(Pyrido(3,4-b)-1,4-oxazinyl-4-yl)-1H-indoler, mellemprodukter og en fremgangsmåde til deres fremstiling, og deres anvendelse som lægemidler
NO178397C (no)	1996-03-20	Substituerte 1,2,3,4-tetrahydrocyklopent[bÅindoler, 1,2,3,3a,4,8a-heksahydrocyklopent[bÅindoler og beslektede forbindelser, mellomprodukter og deres bruk som medikamenter
DK613687A (da)	1988-05-25	Kondenserede heterocycliske tetrahydroaminoquinolinoler og beslaegtede forbindelser, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
DK0405342T3 (da)	1995-05-15	(1,2,3,4-Tetrahydro-9-acridinimino)cyclohexancarboxylsyre og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK0499231T3 (da)	1997-12-01	9-Aminotetrahydroacridiner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
IL111404A (en)	2000-02-17	Pharmaceutical compositions for the enhancement ofmemory and cognition comprising 3-aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles and some such novel compounds
DK0401779T3 (da)	1995-10-16	4,5,5a,6-Tetrahydro-3H-isoazolo(5,4,3-kl)acridinderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler